Viking Therapeutics, Inc. financial data

Symbol
VKTX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 23 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3179% % 1.5%
Debt-to-equity 3.3% % -2.9%
Return On Equity -29% % -130%
Return On Assets -28% % -131%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 113,036,344 shares 1.4%
Common Stock, Shares, Outstanding 112,446,961 shares 0.91%
Entity Public Float $4,004,347,676 USD 4174%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 112,319,770 shares 1.3%
Weighted Average Number of Shares Outstanding, Diluted 112,319,770 shares 1.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $222,484,000 USD 144%
General and Administrative Expense $52,358,000 USD 22%
Operating Income (Loss) $274,842,000 USD -105%
Net Income (Loss) Attributable to Parent $237,394,000 USD -139%
Earnings Per Share, Basic -2 USD/shares -132%
Earnings Per Share, Diluted -2 USD/shares -132%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $100,376,000 USD 99%
Assets, Current $738,703,000 USD -21%
Operating Lease, Right-of-Use Asset $666,000 USD -40%
Assets $739,415,000 USD -21%
Accounts Payable, Current $4,413,000 USD 1637%
Liabilities, Current $26,067,000 USD 1.5%
Operating Lease, Liability, Noncurrent $318,000 USD -58%
Liabilities $26,385,000 USD -0.21%
Retained Earnings (Accumulated Deficit) $689,884,000 USD -52%
Stockholders' Equity Attributable to Parent $713,030,000 USD -22%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $713,030,000 USD -22%
Liabilities and Equity $739,415,000 USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $52,331,000 USD -753%
Net Cash Provided by (Used in) Financing Activities $349,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $63,245,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 112,446,961 shares 0.91%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $164,063,000 USD 38%
Deferred Tax Assets, Gross $164,344,000 USD 38%
Operating Lease, Liability $755,000 USD -39%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $238,652,000 USD -147%
Operating Lease, Liability, Current $437,000 USD -9%
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards $40,799,000 USD 55%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $281,000 USD -11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%